Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-SARS-CoV-2 Equine Serum in Hospitalized COVID-19
NCT04838821Phase 3Unknown
- Sponsor
- Caja Costarricense de Seguro Social
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Antibody Conjugates, scFv Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of equine immunoglobulin anti SARS-CoV-2 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Caja Costarricense de Seguro Social. Primary endpoint: Crude Mortality in COVID-19 patients at day 28. Status: unknown.
02
Drugs
equine immunoglobulin anti SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04838821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838821.